🇺🇸 FDA
Pipeline program

Alirocumab SAR236553

MSC14864

Phase 3 small_molecule completed

Quick answer

Alirocumab SAR236553 for Hypercholesterolaemia is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Hypercholesterolaemia
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials